Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia

20081,607 citationsJournal Article

Authors

Richard F. Schlenk · University Hospital Ulm

Konstanze Döhner · University Hospital Ulm

Jürgen Krauter · Medizinische Hochschule Hannover

Stefan Fröhling · University Hospital Ulm

Andrea Corbacioglu · University Hospital Ulm

Lars Bullinger · University Hospital Ulm

Marianne Habdank

Abstract

Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, and MLL are associated with the outcome of treatment for patients with cytogenetically normal AML.

Topics & Keywords

Acute Myeloid Leukemia Research Protein Degradation and Inhibitors Histone Deacetylase Inhibitors Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 358, Issue 18, pp. 1909-1918

DOI: 10.1056/nejmoa074306

Field-Weighted Citation Impact: 72.23